STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical
Collegium Pharma (COLL) Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA for Nucynta and Nucynta ER streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
STOUGHTON, Mass., April 25, 2024 Collegium Pharmaceutical, Inc. , a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical.
– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – .